Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-14
2006-02-14
Coe, Susan (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S564000
Reexamination Certificate
active
06998396
ABSTRACT:
Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.
REFERENCES:
patent: 4684482 (1987-08-01), Green
patent: 5047329 (1991-09-01), Suzuki
patent: 5047421 (1991-09-01), Green
patent: 5091180 (1992-02-01), Walker et al.
patent: 5721209 (1998-02-01), Horwitz et al.
patent: 5811127 (1998-09-01), Milstein et al.
patent: 6206849 (2001-03-01), Martin et al.
patent: 6383817 (2002-05-01), Schwartz
patent: 6589966 (2003-07-01), Torti et al.
patent: 6706287 (2004-03-01), Ranganathan et al.
patent: 2003/0064929 (2003-04-01), Duranton et al.
patent: 40 08 323 (1991-09-01), None
patent: 05000949 (1993-01-01), None
patent: WO 88/04925 (1988-07-01), None
patent: WO 91/07956 (1991-06-01), None
patent: WO 94/01770 (1994-01-01), None
patent: WO 98/09626 (1998-03-01), None
patent: WO 00/13706 (2000-03-01), None
patent: WO 00/54784 (2000-09-01), None
Fernández-Real, J.M., et al., “Cross-Talk Between Iron Metabolism and Diabetes,”Diabetes, 51:2348-2354, 2002.
Nitenberg, A., et al., “Coronary Microvascular Adaptation to Myocardial Metabolic Demand Can Be Restored by Inhibition of Iron-Catalyzed Formation of Oxygen Free Radicals in Type 2 Diabetic Patients,”Diabetes, 51:813-818, 2002.
Sumboonnanonda, A., et al., “Renal tubular function in β-thalassemia”,Pediatr Nephrol, 12:280-283.
Ong-ajyooth, L., et al., “Renal Function in Adult Beta-Thalassemia/Hb E Disease”,Nephron, 78:156-161 (1998).
Guasch, A., et al., “Evidence that Microdeletions in the αGlobin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans”,J Am Soc Nephrol, 10:1014-1019 (1999).
Loebstein, R., et al., “Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia”,Diabetes Care, 21(8):1306-1309 (1998).
Ongajyooth, L., et al., “Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome”,J Med Assoc Thai, 78(3):119-126 (1995).
Aoki, R.Y., et al., “Microalbuminuria in Sickle Cell Disease”,Brazilian J Med Biol Res, 23:1103-1106 (1990).
Katopodis, K.P., et al., “Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia”,Journal of Nephrology10(3):163-167 (1997).
Pham, P.-T.T., et al., “Renal abnormalities in sickle cell disease”,Kidney International, 57:1-8 (2000).
Kontoghiorghes, G.J., et al., “Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones”,Inorganica Chimica Acta, 136:L11-L12 (1987).
Falk, R.J., et al., “Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Convertng Enzyme”,The New England Journal of Medicine, 326(14):910-915 (1992).
Guasch, A., et al., “Sickle cell anemia causes a distinct pattern of glomerular dysfunction”,Kidney International, 51:826-833 (1997).
Cianciulli, P., et al., “Early detection of nephrotoxic effets in thalassemic patients receiving desferrioxamine therapy”,Kidney International, 46:467-470 (1994).
Ueda, N., et al., “Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndrome”,Kidney International, 49:370-373 (1996).
Savill, J., et al., “Mechanisms of glomerular injury”. In “Oxford Textbook of Clinical Nephrology,” 2nded., pp. 404-439, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
Ueda, N., et al., “In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease”,Kidney: A Current Survey of World Literature, 6:143-146 (1997).
Boyce, N.W., et al., “Hydroxyl radical mediation of immune renal injury by desferrioxamine”,Kidney International, 30:813-817 (1986).
Baliga, R., et al., “Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet”,J Am Soc Nephrol, 7(8):1183-1188 (1996).
Shah, S.V., “Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats”,The American Physiological Society, F337-F344(1988).
Thakur, V., et al., “Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria”,Kidney International, 34:494-499 (1988).
Nankivell, B.J., et al., “The Role of Tubular Iron Accumulation in the Remnant Kidney”,J Am Soc Nephrol, 4(8):1598-1607 (1994).
Alfrey, A.C., et al., “Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis”,Kidney International, 36:753-759 (1989).
El Nahas, A.M., “Mechanisms of experimental and clinical renal scarring” In: “Oxford Textbook of Clinical Nephrology”, 2nded., pp. 1749-1788, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
Howard R.L., et al., “Urinary albumin, transferrin and iron excretion in diabetic patients”,International Society of Nephrology, 40:923-926 (1991).
Olivieri, N.F., et al., “Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major”,The New England Journal of Medicine, 918-922 (1995).
Alfrey A.C., “Toxicity of tubule fluid iron in the nephrotic syndrome”,American Journal of Physiology, 263(4):F637-F641 (1992).
Wu, Z-L, et al., “Iron Loading Enhances Susceptibility to Renal Ischemia in Rats,”Renal Failure, 16(4): 471-480 (1994).
Baliga, R., et al., “In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity,”Kidney International, 53(2): 394-401 (Feb. 1998).
Harris, D., et al., “Mitrochondrial Function in Rat Renal Cortex in REsponse to Proteinuria and Iron,”Clinical and Experimental Pharmacology and Physiology24:916-922 (Dec. 1997).
Walker, P.D., et al., “Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats,”J Clin Invest81:334-341 (1988).
Shah, S.V., et al., “Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure,”Am J Physiol 255, (Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).
Baliga, R., et al., “Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys,”Biochem J291 (3):901-905 (1993).
Kontoghiorghese, G.J., et al., “Studies of Aluminium Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one,”Arzneim-Forsh/Drug Res. 44(1):522-526 (1994).
Baliga, R., et al., “Oxidant Mechanisms in Toxic Acute Renal Failure,”Drug Metabolism Reviews31(4):971-991 (1999).
Walker, P.D., et al., “Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria,”Am J Physiol253:C495-C499 (1987).
Walker, P.D., et al., “Hydrogen Peroxide Cytotoxicity in LLC-PK1Cells: A Role for Iron,”Kidney Int40:891-898 (1991).
Abul-Ezz, S.R., et al., “Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure,”Proc Natl Acad Sci88:9833-9837 (1991).
Ueda, N., et al., “Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria,”Am J Physiol265(3 Pt. 2):F435-F439 (1993).
Baliga, R., et al., “Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure,”Kidney Int49:362-369 (1996).
Baliga, R.,
Coe Susan
Shiva Biomedical LLC
Winston Randall
LandOfFree
Diagnosis and treatment of human kidney diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and treatment of human kidney diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of human kidney diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682051